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Abstract
Background: Total knee arthroplasty (TKA) is associated with intense and long-duration pain. Research is currently
being conducted on the use of liposome bupivacaine (LB) to prolong the effects of local infiltration anesthesia. This
systematic review and meta-analysis of randomized controlled trials (RCTs) evaluated the efficacy and safety of pain
control of using LB versus placebo after TKA.
Methods: In April 2016, the Medline, Embase, PubMed, Cochrane Controlled Trials Register (CENTRAL), Web of
Science, Google database, and Chinese Wanfang databases were searched to identify articles that compare a LB
group versus a control group for pain control after TKA. This systematic review and meta-analysis were performed
according to the PRISMA statement criteria. The primary endpoint was the visual analogue scale (VAS) score after
TKA at 24, 48, and 72 h. The second outcome was nausea complications, which represent morphine-related side
effects. Stata 12.0 software was used for the meta-analysis.
Results: Five studies involving 574 patients met the inclusion criteria. The meta-analysis revealed that LB can
decrease the VAS score at 24 h (mean difference (MD) = −0.50; 95 % CI −0.97 to −0.04; P = 0.034), 48 h (MD = −0.26;
95 % CI −0.71 to 0.19; P = 0.256), and 72 h (MD = −0.26; 95 % CI −0.71 to 0.19; P = 0.256). There was no significant
difference with respect to the length of hospital stay (MD = −0.08; 95 % CI −0.28 to 0.13; P = 0.475). Furthermore, LB
can reduce the occurrence of nausea (RR = 0.38; 95 % CI 0.18 to 0.79; P = 0.009).
Conclusions: Based on the current meta-analysis, LB as a novel anesthetic formulation administration following TKA
demonstrated better pain control; however, the sample size was limited, and further RCTs are needed to identify
the effects of LB after TKA.
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Background
Total knee arthroplasty (TKA) is a common surgical
procedure that causes moderate to severe pain and is
considered a challenge to manage due to its intensity
and duration [1, 2]. Inadequate pain control after TKA
is associated with poor postoperative recovery, an in-
crease in the length of hospital stay, and higher patient
dissatisfaction and hospital costs [3, 4]. Many analgesia
techniques, such as femoral nerve block, epidural infu-
sions, oral morphine, peri-articular infiltration analgesia,
and adductor canal block, have been used to control
pain after TKA [5, 6]. Multimodal analgesia including
local infiltration analgesia has been identified as the
most preferred method for pain control after TKA [7].
These methods not only reduce the pain intensity but
also decrease opioid consumption and thereby reduce
the occurrence of the morphine-related complications
such as nausea, vomiting, and respiration depression [8].
Bupivacaine HCL has been used in many surgical pro-
cedures as a local anesthetic due to its long-acting ef-
fects. However, even with the addition of epinephrine to
prolong the duration of the analgesic effects, these ef-
fects remain limited [9]. Liposome bupivacaine (LB) is a
novel local anesthetic that enables the extended release
of bupivacaine into surgical sites to extend analgesic ef-
fects. The mechanism of LB to extend analgesia effects
uses DepoFoam® as a delivery platform; thus, bupiva-
caine can be released over 72 h [10]. LB has been used
to control pain after TKA; however, there is no
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consensus regarding the pain control effects of LB after
TKA. Thus, a systematic review and meta-analysis was




A comprehensive search for all relevant studies compar-
ing LB with control after primary TKA was conducted
using the electronic databases PubMed, Embase, the
Cochrane Library, and Wanfang database from their in-
ception until April 2016. Relevant studies were also
manually searched in reviews and gray literature, and
this process was halted when no additional articles could
be added. The search terms were as follows: “total knee
arthroplasty,” “total knee replacement,” “TKA,” “TKR,”
“Arthroplasty, Replacement, Knee[Mesh],” and “lipo-
some bupivacaine.” These key words and the corre-
sponding medical subject heading (MeSH) terms were
combined with the Boolean operators AND and OR.
There were no restrictions regarding the language or
year of publication.
Inclusion criteria and study selection
All randomized controlled trials (RCTs) comparing LB
with control were eligible for this meta-analysis. If there
was more than one eligible trial from one team, the
study with the most recent publication data was enrolled
for analysis. Studies with bilateral TKA, TKA revision,
or administration with other anesthetic methods were
excluded. All non-randomized trials were also excluded.
Data extraction
Two reviewers extracted data independently using a pre-
defined data extraction form. Disagreements were re-
solved by discussion or consensus with a third reviewer.
The data extracted included the first author, publication
years, study characteristics (number of patients and per-
centage of female patients), participant characteristics
(i.e., mean age, anesthesia, operative approach, and type
of prosthesis), and the length of follow-up. For studies
with insufficient information, the reviewers attempted to
contact the first author via e-mail or telephone to obtain
the original data. After duplicates were excluded, two re-
viewers independently read the titles and abstracts of the
searched literature. Most of the articles were excluded
based on the topic of the article provided in the respect-
ive title or abstract, and disagreements regarding
whether an article should be included were resolved in
discussion or by a senior reviewer. Postoperative pain in-
tensity was measured using a 100-point visual analogue
scale (VAS). The 10-point VAS score was converted to a
100-point VAS score. Data in other forms (i.e., median,
interquartile range, and mean ± 95 % CI) were converted
to means ± SD according to the Cochrane Handbook. If
the data were not reported numerically, we extracted
them using the GetData Graph Digitizer software from
the published figures.
Quality assessment
Two independent reviewers assessed the methodological
quality of the included trials according to the Cochrane
Collaboration recommendations. The following informa-
tion was evaluated: random sequence generation, alloca-
tion concealment, blinding of outcome assessments,
incomplete outcome data, selective reporting, and other
biases. An independent arbiter was consulted to recon-
cile any disagreements.
Statistical analysis
Continuous outcomes, such as the VAS at 24, 48, and
72 h and the length of hospital stay, were expressed as
the mean difference (MD) with respective 95 % CIs. Dis-
continuous outcomes (the rate of nausea) were
expressed as the relative risk (RR) with 95 % CIs. Statis-
tical significance was set at P < 0.05 to summarize find-
ings across the trials. Software Stata 12.0 (Stata Corp.,
College Station, TX) was used for the meta-analysis.
Statistical heterogeneity was tested using the chi-squared
test and I2 statistic. A chi-squared test I2 > 50 % was con-
sidered suggestive of statistical heterogeneity; thus, a
random effects model was adopted and further subgroup
analysis or sensitivity analysis was conducted to seek out
the potential source of heterogeneity. When there was




In the initial research, 125 potentially relevant trials were
identified and 32 duplications were removed using the
software Endnote X7 (Thomson Research Soft Com-
pany, America). Finally, the title and abstract of the 93
articles were reviewed and included according to the in-
clusion criteria (detailed search criteria can be found in
Fig. 1). During the search process, a total of three dis-
agreements occurred; these were resolved by the senior
author following review of the full article. Finally, only
five RCTs were included for the meta-analysis [11–15].
One study compared four different doses of LB with a
control group; this study was divided into four trials
[11]. Thus, eight studies with a total of 574 patients in-
volving 276 LB patients and 298 control patients were fi-
nally included in this meta-analysis. All selected patients
were in English and published between 2012 and 2016.
The detailed characteristics of the included studies are
shown in Table 1.
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VAS score at 24 h
Five trials reported a VAS score at 24 h for the LB group
and control group. Pooled results indicated that LB was
associated with a lower VAS score at 24 h after TKA
(MD = −0.50; 95 % CI −0.97 to −0.04; P = 0.034, Fig. 2)
with no heterogeneity (P = 0.072, I2 = 0.0 %).
VAS score at 48 h
Pooled results indicated no significant difference be-
tween the LB and control group after TKA in terms of
VAS score at 48 h (MD = −0.26; 95 % CI −0.71 to
0.19; P = 0.256, Fig. 3) with no heterogeneity (P = 0.456,
I2 = 0.0 %).
VAS score at 72 h
Five trials consisting of 354 patients reported the VAS
score at 72 h for the LB group and control group. The
meta-analysis indicated that peri-articular infiltration LB
can decrease the VAS score at 72 h (MD = −0.26; 95 %
CI −0.71 to 0.19; P = 0.256, Fig. 4) with low heterogen-
eity (P = 0.261, I2 = 24.1 %). A sensitivity analysis after ex-
cluding one trial with no heterogeneity demonstrated a
significant difference between the two groups (MD= −0.26;
95 % CI −1.75 to 0.35; P = 0.003), a result that is in line
with previous analysis.
Length of hospital stay
Two studies reported the length of hospital stay in the
two groups. There was no significant difference between
the LB and control group in terms of the length of hos-
pital stay (MD = −0.08; 95 % CI −0.28 to 0.13; P = 0.475,
Fig. 5) with a high heterogeneity (P = 0.475, I2 = 84.2 %).
However, because there were only two trials, a sensitivity
analysis was not conducted.
The occurrence of nausea
The meta-analysis indicated that LB can decrease the oc-
currence of nausea (RR = 0.38; 95 % CI 0.18 to 0.79;
P = 0.009, Fig. 6) with a high heterogeneity (P = 0.000,
I2 = 90.3 %). A random effects model was thus
adopted to further analyze the results. Furthermore, a
sensitivity analysis was conducted to determine which
study contributed to the final large heterogeneity;
however, the sensitivity analysis indicated that no tri-
als influenced the final heterogeneity.
Discussion
To our knowledge, this is the first systematic review and
meta-analysis of RCTs comparing LB with a control in
the management of pain after TKA. Only RCTs of high
quality were included for the meta-analysis, which
strengthens the credibility of our results. This comparative
Fig. 1 The search strategies of the included studies
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Table 1 The general characteristic of the included studies
Author Country No. of patients Female (%) Age (mean) Anesthesia Approach Use of cement Indication of pain Follow-up
(month)Total LB CO LB CO LB CO
Bramlett 2012 [11] 133mg USA 62 28 34 53.6 67.6 61.4 62.2 General anesthesia NS NS NRS 1
Bramlett 2012 [11] 266mg USA 59 25 34 48 67.6 61.1 62.2 General anesthesia NS NS NRS 1
Bramlett 2012 [11] 399mg USA 60 26 34 57.7 67.6 61.8 62.2 General anesthesia NS NS NRS 1
Bramlett 2012 [11] 532mg USA 59 25 34 80 67.6 64.9 62.2 General anesthesia NS NS NRS 1
Collis 2016 [15] USA 105 54 51 53.7 72.5 63 63 General anesthesia Subvastus approach NS VAS NS
Schroer 2015 [12] USA 111 58 53 59 60 67 68.6 Spinal or general anesthesia Mini-subvastus approach Cemented VAS 0.75
Schwarzkopf 2016 [13] USA 38 20 18 67 43 63 59 Spinal anesthesia Medial parapatellar approach Cemented VAS NS
Surdam 2015 [14] USA 80 40 40 57.5 52.5 64.9 68.4 Spinal anesthesia NS Cemented Patient self-rated 0–10 pain
scale and the Wong–Baker
pain faces scale
10















and retrospective study presents selective risk bias regard-
ing the final results. All of the included studies were pub-
lished after 2012, and most trials were published in 2015
and 2016. Of all the included studies, only one trial was
randomized via random sequence generation, and one
study performed allocation using sealed envelopes. Three
studies were double-blinded to the participants and pa-
tients. All of the studies completed the outcome data, and
selective reporting and other biases are not clear. Detailed
information on the included studies can be found in
Table 2. Pain intensity was measured as VAS score at 24,
48, and 72 h after TKA, and the results indicated that
peri-articular administration LB can decrease the VAS
score at 24, 48, and 72 h. However, there is no significant
difference between the two groups in terms of VAS score
at 48 h. There are insufficient data regarding long-term
Fig. 3 Forest plot comparing VAS score at 48 h between the LB group and control group
Fig. 2 Forest plot of comparison: VAS score at 24 h between the LB group and control group
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pain control of LB with placebo in the included studies;
long-term follow-ups are needed. Regarding the length of
hospital stay, because a total of two studies reported rele-
vant data, there was no significant difference between the
two groups. Furthermore, LB can also decrease the occur-
rence of nausea with statistical significance.
LB was recently introduced to multiple anesthesia
with the intention of improving the analgesic effects of
peri-articular infiltration (PAI) anesthesia by increasing
the duration and consistency of action. However, recent
studies support indeterminate efficacy of LB versus
PAI. In this meta-analysis, LB can decrease the pain in-
tensity at 24, 48, and 72 h after TKA. Cien et al. [16]
compared LB versus femoral nerve block after TKA
and found that LB can reduce hospital costs and opioid
consumption. Liposomes are commonly used drug car-
riers that offer biologically active drugs with long-term
potency and a reduction in toxicity [17]. LB consists of
microscopic, spherical multi-vesicular lipid-based parti-
cles that form honeycomb-like aqueous chambers. This
Fig. 5 Forest plot comparing the length of hospital stay between the LB group and control group
Fig. 4 Forest plot comparing VAS score at 72 h between the LB group and control group
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structure combined with bupivacaine enables the diffu-
sion of bupivacaine in the knee joints over 96 h after a
single administration. As a natural evolution, LB is now
being proposed to offer benefits in TKA [18]. However,
when comparing PAI in LB with a multimodal pain
management protocol with bupivacaine, epinephrine,
and morphine, the pain score in the LB group is higher
than that in the control group [10]. Thus, solely peri-
articular LB is not sufficient to achieve the most ideal
anesthetic effect.
LB can lead to shortened hospital stay; however, this
difference was not statistically significant because the
samples and included trials were limited and the length
of hospital stay is affected by many factors. Chughtai
et al. [19] used a large hospital database to determine
whether LB can reduce hospital stay length and found
that the length of hospital stay (LOS) in the LB group
was 2.58 days; this length was 2.98 days in the non-
injection group. In contrast, Schroer et al. [12] found a
benefit for multimodal LB suspension injection versus
bupivacaine HCL; however, there were no significant dif-
ferences between the pain score at 24, 48, and 72 h. Fur-
thermore, the cost of LB was higher than that of the
control group, so the authors did not recommend rou-
tine LB. However, a statistically significant difference
may have not been achieved because the sample size
may have not allowed for adequate power. Additionally,
Schroer et al. [12] did not determine the LOS or dis-
charge outcome. The difference in cost may be balanced
by the shorter LOS in this meta-analysis.
Nausea and vomiting are common complications that
usually occur following oral or intravenous morphine.
Multimodal anesthetic techniques can reduce the con-
sumption of morphine and subsequent morphine-related
complications. If patients have better pain control with
local infiltration analgesia, the consumption of morphine
will decrease correspondingly. Our meta-analysis indicated
that local infiltration with LB can also reduce nausea.
There are several limitations to this meta-analysis: (1)
only five RCTs were included, and the sample sizes in
Table 2 The quality assessment for the included studies
Trials Random sequence generation Allocation concealment Blinding Complete
outcome data
Selective reporting Other bias
Bramlett 2012 [11] Centralized randomization
system
Unclear Yes Yes Unclear Unclear
Collis 2016 [15] Unclear Unclear Yes Yes No Unclear
Schroer 2015 [12] Unclear Unclear Yes Yes Unclear Unclear
Schwarzkopf 2016 [13] Unclear Unclear Unclear Yes Unclear Unclear
Surdam 2015 [14] Unclear Sealed envelopes No Yes Unclear Unclear
Fig. 6 Forest plot comparing the occurrence of nausea between the LB group and control group
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each trial were small, which would affect the final re-
sults; (2) the duration of follow-up in some studies was
unclear, and long-term follow-up was needed for this
analysis; (3) the publication bias of the meta-analysis also
influenced the results; and (4) the dose of LB and the
randomized generation sequence were not reported in
some trials.
Conclusions
In conclusion, this was the first systematic review to
evaluate the efficacy and safety of using LB compared
with placebo for reducing pain after TKA. Our meta-
analysis indicates that LB may be more effective in pain
control at 24, 48, and 72 h compared with using a pla-
cebo after TKA. The most important finding of this
study is that LB may shorten the hospital stay and re-
duce the occurrence of nausea. In future research, an
optimal dose of LB should be rigorously defined, and the
perioperative multimodal anesthesia should also be clari-
fied. More importantly, well-designed trials with larger
sample sizes are needed to provide further reliable evi-
dence for the safety of LB for pain management, knee
flexion, and other outcomes after TKA.
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